IGF-1 and Longevity: The Goldilocks Hormone You Should Be Tracking

You've probably heard that growth is good. More muscle, faster recovery, better repair. But when it comes to aging, the hormone that drives growth operates on a different set of rules. Too much insulin-like growth factor 1 (IGF-1) and you're accelerating cellular division in ways that raise cancer risk (low IGF-1 predicts survival in humans with exceptional longevity) (IGF-1 and cancer risk research). Too little and you're losing the anabolic signal that keeps muscle intact, bones dense, and tissues resilient. The longevity sweet spot sits somewhere in the middle, and most people have no idea where they land (Nature Reviews Endocrinology: the GH/IGF-1 axis in ageing and longevity) (Mayo Clinic on growth hormone and aging) (IGF-1 system in longevity from a centenarian perspective).

Key Takeaways

• IGF-1 drives cellular growth and repair but declines steadily with age.
• Both high and low IGF-1 levels increase mortality risk in a U-shaped pattern.
• Elevated IGF-1 is linked to higher cancer risk across multiple tissue types.
• Low IGF-1 in older adults predicts frailty, sarcopenia, and cognitive decline.
• Optimal IGF-1 levels vary by age and shift across the lifespan.
• Protein intake and caloric load are the strongest dietary modulators of IGF-1.
• Tracking IGF-1 over time reveals your anabolic trajectory and longevity risk profile.

What IGF-1 Actually Does in the Body

IGF-1 is a peptide hormone produced primarily in the liver in response to growth hormone signaling. It binds to receptors on nearly every cell type in the body and activates pathways that promote cell division, protein synthesis, and tissue growth. In childhood and adolescence, IGF-1 drives linear growth and skeletal maturation. In adulthood, it maintains muscle mass, supports bone remodeling, facilitates wound healing, and regulates glucose metabolism.

At the cellular level, IGF-1 activates the PI3K-AKT-mTOR pathway, a central regulator of anabolic metabolism. This pathway promotes protein translation, inhibits autophagy, and increases cellular proliferation. These effects are beneficial when tissues need to grow or repair. But when IGF-1 signaling remains chronically elevated, the same pathways that build tissue can also accelerate the replication of damaged or precancerous cells. IGF-1 also suppresses apoptosis (the programmed cell death mechanism that normally clears out dysfunctional cells). This dual role makes IGF-1 essential for health in the short term but potentially problematic for longevity when levels stay high across decades.

IGF-1 levels peak in late adolescence and decline progressively with age:

• By age 50, circulating IGF-1 is roughly half of what it was at age 20.
• By age 80, it drops further still.
• This decline contributes to muscle loss, slower wound healing, and reduced bone density in older adults.
• The decline also appears protective against cancer, which is why the relationship between IGF-1 and longevity is not linear.

How IGF-1 Connects to the Hallmarks of Aging

IGF-1 sits at the intersection of multiple aging pathways. Its role in nutrient sensing links it directly to deregulated nutrient sensing, one of the primary hallmarks of aging. When IGF-1 signaling is chronically active, it keeps mTOR turned on, which suppresses autophagy and prevents cells from clearing damaged proteins and organelles. This contributes to loss of proteostasis, the breakdown of protein quality control that accelerates cellular dysfunction.

Elevated IGF-1 also promotes cellular senescence indirectly by driving proliferation in cells that have accumulated DNA damage. Senescent cells stop dividing but remain metabolically active, secreting inflammatory cytokines that contribute to chronic inflammation and tissue degradation. High IGF-1 accelerates this process by pushing damaged cells through additional rounds of replication before they enter senescence, increasing the burden of dysfunctional cells in aging tissues.

On the other end of the spectrum, very low IGF-1 impairs stem cell function and reduces the regenerative capacity of tissues. This contributes to stem cell exhaustion, another hallmark of aging. Without adequate IGF-1 signaling:

• Muscle satellite cells fail to activate in response to injury.
• Bone marrow stem cells produce fewer immune cells.
• Neural progenitor cells show reduced neurogenesis.
• The result is a loss of tissue resilience and increased vulnerability to frailty.

What Drives IGF-1 Levels

Protein intake and amino acid signaling

Dietary protein is the strongest modulator of circulating IGF-1. High protein intake, particularly from animal sources, stimulates hepatic IGF-1 production through amino acid sensing pathways. Leucine activates mTOR and upregulates IGF-1 synthesis. Populations consuming high-protein diets show higher average IGF-1 levels, while those following plant-based or calorie-restricted diets show lower levels. This is one reason why protein restriction during midlife has been proposed as a longevity intervention, though the evidence in humans remains mixed.

Caloric intake and metabolic load

Total caloric intake influences IGF-1 independent of protein content. Caloric restriction consistently lowers IGF-1 in animal models and human studies, even when protein intake is held constant. This effect is mediated through reduced growth hormone secretion and decreased hepatic IGF-1 production. Conversely, chronic overfeeding and obesity are associated with elevated IGF-1, particularly in younger adults. The metabolic stress of excess caloric load appears to sustain anabolic signaling pathways that would otherwise decline with age.

Exercise and physical activity

Resistance training acutely increases IGF-1 expression in muscle tissue, where it promotes hypertrophy and repair. Systemic IGF-1 levels may rise transiently after intense exercise but tend to normalize or even decline with chronic training. Aerobic exercise has a more modest effect on IGF-1, though it improves insulin sensitivity, which modulates IGF-1 bioavailability. The net effect of regular exercise on IGF-1 depends on training volume, intensity, and baseline metabolic health.

Sleep and circadian rhythm

Growth hormone is secreted in pulses during deep sleep, and IGF-1 production follows this circadian pattern. Chronic sleep deprivation blunts growth hormone secretion and lowers IGF-1, particularly in younger adults. In older adults, the relationship is less clear, as growth hormone secretion declines with age regardless of sleep quality. Circadian disruption from shift work or irregular sleep schedules also impairs the normal pulsatility of growth hormone and may contribute to dysregulated IGF-1 signaling over time.

Why IGF-1 Responses Vary Between Individuals

Genetics account for a significant portion of the variation in circulating IGF-1 levels. Polymorphisms in the IGF-1 gene itself, as well as in genes encoding IGF-1 receptors and binding proteins, influence both baseline levels and the rate of age-related decline. Some individuals maintain relatively high IGF-1 into older age, while others show steep declines starting in midlife. These genetic differences interact with diet, body composition, and metabolic health to determine an individual's IGF-1 trajectory.

Sex hormones also modulate IGF-1. Estrogen increases hepatic production of IGF-1, which is why premenopausal women tend to have higher levels than age-matched men. After menopause, IGF-1 declines more sharply in women, contributing to accelerated bone loss and muscle atrophy. Testosterone also influences IGF-1, though the relationship is bidirectional. Low testosterone is associated with lower IGF-1, and IGF-1 itself supports testicular function and androgen production.

Metabolic phenotype plays a major role. Insulin resistance reduces the bioavailability of IGF-1 by altering the balance of IGF-1 binding proteins. Individuals with metabolic syndrome or type 2 diabetes often show paradoxically low IGF-1 despite high caloric intake, because insulin resistance impairs the liver's ability to produce IGF-1 in response to growth hormone. This creates a metabolic environment where anabolic signaling is blunted, contributing to sarcopenia and frailty even in the presence of obesity.

What the Evidence Actually Shows

Large cohort studies consistently demonstrate a U-shaped relationship between IGF-1 and all-cause mortality. Both very high and very low levels predict increased death rates compared to mid-range values. This pattern holds across age groups, though the optimal range shifts slightly higher in older adults.

Elevated IGF-1 (typically above 200-250 ng/mL in adults) correlates with increased cancer incidence, particularly for breast, prostate, and colorectal cancers. The mechanism involves sustained activation of proliferative pathways in tissues with high cell turnover, where even small increases in replication rate compound over decades. Importantly, the association is strongest in midlife, when cancer incidence begins to rise. In older adults, the relationship weakens, likely because competing risks from frailty and cardiovascular disease become more prominent.

On the low end, IGF-1 below 100 ng/mL in adults over 65 predicts higher rates of hospitalization, functional decline, and mortality from non-cancer causes. Low IGF-1 in this population is a marker of anabolic insufficiency, where the body lacks the hormonal signal needed to maintain muscle, bone, and immune function. This is why the longevity literature emphasizes context: what protects against cancer in midlife may accelerate frailty in late life.

The middle range (roughly 120 to 180 ng/mL depending on age) appears to balance cancer risk and anabolic sufficiency across most of adulthood, though individual variation means these thresholds should be interpreted alongside other metabolic markers and clinical context.

How to Use IGF-1 Data to Inform Your Longevity Strategy

Tracking IGF-1 over time provides insight into your anabolic trajectory and helps identify whether you're at risk for the high end or low end of the U-shaped curve. A single measurement is a snapshot. Serial measurements reveal whether your levels are stable, declining faster than expected, or remaining elevated into an age range where cancer risk becomes more relevant.

For adults under 50 with IGF-1 consistently above 250 ng/mL, the data suggest a higher lifetime cancer risk, particularly if there is a family history of hormone-sensitive cancers. Interventions that modulate IGF-1 in this population include:

• Reducing animal protein intake and increasing plant-based protein sources.
• Avoiding chronic caloric surplus.
• Implementing time-restricted eating or periodic fasting to reduce the frequency of mTOR activation.

For adults over 65 with IGF-1 below 100 ng/mL, the priority shifts to preserving anabolic capacity. This means ensuring adequate protein intake (particularly leucine-rich sources) and incorporating resistance training to stimulate local IGF-1 expression in muscle tissue. In this context, higher protein intake is protective, not harmful, because the goal is to prevent sarcopenia and maintain functional independence.

Individuals in the middle range should focus on maintaining metabolic health, insulin sensitivity, and body composition, all of which influence how IGF-1 is produced and utilized at the tissue level.

Measuring What Matters for How You Age

If you want to understand how your body is managing the trade-off between growth and longevity, IGF-1 is one of the most informative markers you can track. It reflects your dietary patterns, metabolic health, and anabolic reserve in a single number. But it's not a marker you measure once and forget. The trajectory matters more than the snapshot. Superpower's 100+ biomarker panel includes IGF-1 alongside markers of insulin sensitivity, inflammation, and body composition, giving you a complete picture of how your metabolism is aging. Tracking these markers over time lets you see whether your interventions are moving you toward the longevity sweet spot or pushing you toward one end of the risk curve.